An Intensive Follow-Up in Surgically Treated Patients for Endometrial Cancer Does Not Improve Overall Survival, Even in High-Risk Setting
Findings from the TOTEM study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
EMA Recommends Granting a Marketing Authorisation for Melphalan Flufenamide for the Treatment of Multiple Myeloma
Melphalan flufenamide is a lipophilic derivative of melphalan designed to enhance cell penetration
Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance Prolongs PFS in Newly Diagnosed Multiple Myeloma
Primary data from the DETERMINATION study
First-Line Treatment with Pembrolizumab-Chemotherapy Results in Longer OS than Chemotherapy Alone for Advanced TNBC with PD-L1 CPS of 10 or More
Data from a final analysis of the KEYNOTE-355 study
FDA Approves Crizotinib for ALK-positive Inflammatory Myofibroblastic Tumour
Crizotinib received orphan drug designation
No OS Benefit for Active Maintenance Treatment with Olaparib Relative to Placebo in Patients with Metastatic Pancreatic Cancer and a Germline BRCA Mutation
Final overall survival results of the POLO study
EMA Recommends Extension of Indications for Trastuzumab Deruxtecan
New indication concerns the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2 based regimens
Anticancer Drugs in the Adjuvant Setting Have Considerable Costs Per Event Averted, Raising Questions of Sustainability
Adjuvant therapies are often approved based on composite, surrogate endpoints with high costs per event averted
Patients with Advanced Hodgkin’s Lymphoma Treated with Brentuximab Vedotin Plus AVD Have a Survival Advantage Over Those Who Received ABVD Regimen
Data from a median of 6 years follow-up from the ECHELON-1 study
Only a Quarter of Phase III Studies Demonstrated Improved QoL in Advanced Cancer Setting
Clinical study publications frequently frame unimproved quality of life outcomes in a positive way
EMA Recommends Extension of Therapeutic Indications for Ibrutinib
New indication concerns its use in combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia
Trastuzumab Deruxtecan Leads to Longer PFS and OS Compared with Chemotherapy in Previously Treated HER2-Low Unresectable or Metastatic Breast Cancer
Practice changing results of the DESTINY-Breast04 study